Advertisement

Organisation › Details
Novartis (Group)
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. *
![]() |
Start | 1996-12-20 merged |
Predecessor | Ciba-Geigy (Group) | |
![]() |
Industry | CHEMICALS |
![]() |
Person | Narasimhan, Vasant (Vas) (Novartis 201408– Global Head Developm Novartis Pharma before Global Head Developm Vaccines |
Person 2 | Reinhardt, Jörg (Novartis 201308– Board Chairman before Bayer 201008– CEO Bayer HealthCare AG before Novartis COO) | |
![]() |
Region | Basel BS |
Country | Switzerland | |
City | 4002 Basel BS | |
Tel | +41-61-324-2200 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | J: more than 100,0 (2019-12-31) |
Currency | USD | |
Annual sales | 47,498,000,000 (sales, net, continued operations, consolidated (2019) 2019-12-31) | |
Profit | 7,147,000,000 (2019-12-31) | |
Cash | 9,485,000,000 (2017-12-31) | |
* Document for »About Section«: | ||
Record changed: 2024-12-29 |
Advertisement

More documents for Novartis (Group)
- [1] Anthos Therapeutics, Inc.. (2/11/25). "Press Release: Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 billion". Cambridge, MA....
- [2] Novartis AG. (2/11/25). "Press Release: Novartis Bolsters Late-stage Cardiovascular Pipeline with Agreement to Acquire Anthos Therapeutics for USD 925 Million Upfront". Basel....
- [3] Sanofi S.A.. (12/19/24). "Press Release: Jean-Paul Kress to Join Sanofi’s Board of Directors". Paris....
- [4] BioAge Labs, Inc.. (12/18/24). "Press Release: BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions". Richmond, CA....
- [5] Eckert & Ziegler SE. (12/13/24). "Press Release: Eckert & Ziegler Submits GalliaPharm for Approval by Japan’s Health Authority MHLW". Berlin....
- [6] Siemens Healthineers AG. (12/10/24). "Press Release: Siemens Healthineers Acquires Advanced Accelerator Applications Molecular Imaging"....
- [7] PTC Therapeutics, Inc.. (12/2/24). "Press Release: PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program". Warren, NJ....
- [8] Novartis AG. (11/21/24). "Press Release: Addressing Unmet Needs for Inherited Neuromuscular Diseases. Novartis Has Acquired Kate Therapeutics to Further Enhance and Strengthen Our Ongoing Efforts to Advance Gene Therapies for Patients"....
- [9] VarmX B.V.. (11/12/24). "Press Release: VarmX Announces Appointment of John Glasspool as CEO". Leiden....
- [10] Generative:Biomedicines. (9/24/24). "Press Release: Generate:Biomedicines Announces Multi-Target Collaboration with Novartis to Discover and Develop Protein Therapeutics with Generative AI". Somerville, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top